Opendata, web and dolomites

PanINSULA

PanINSULA - The next first commercially sustainable and therapeutically effective beta cell therapy for diabetes

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PanINSULA project word cloud

Explore the words cloud of the PanINSULA project. It provides you a very rough idea of what is the project "PanINSULA" about.

inactivity    cadaveric    islets    death    care    commercially    treatment    physical    levels    transplantation    clinically    fluctuations    premature    blood    amputations    careful    serious    scalable    protection    complications    contrast    limited    day    region    stem    lifetime    cure    nerve    damaged    cell    steady    implanted    producing    severe    automation    efficient    islet    sugar    patented    chronic    generating    scalability    insulin    overweight    unparalleled    hurdles    therapy    self    pancryos    patients    difficulties    accounts    manufacturability    cope    blindness    natural    ages    disease    population    damage    safety    emerged    diabetes    kidney    keeping    hyperglycemia    risk    purity    time    pluripotent    permanent    mostly    people    positions       diet    paninsula    regulate    inject    final    beta    lack    prevalence    last    shortage    purification    glucose    lifethreatening    unhealthy    t1d    immune    cells    hpscs    competing    heart    times    intensive    replace    technologies    donor    10    secretion    obesity   

Project "PanINSULA" data sheet

The following table provides information about the project.

Coordinator
PANCRYOS IVS 

Organization address
address: OLE MAALOES VEJ 3
city: KOBENHAVN N
postcode: 2200
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Project website http://www.pancryos.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-08-01   to  2018-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PANCRYOS IVS DK (KOBENHAVN N) coordinator 50˙000.00

Map

 Project objective

Prevalence of diabetes is increasing among all ages in the European Region, mostly due to increases in overweight and obesity, unhealthy diet and physical inactivity. Today there are about 60 M people with diabetes in the EU, of which Type 1 Diabetes (T1D) accounts for between 5% and 10%. T1D patients must cope with a lifetime of intensive self-care (testing their blood sugar levels several times a day to inject insulin when required) and the risk of premature death. Even with careful management T1D patients can still have difficulties keeping a steady blood glucose level and over time these lifethreatening fluctuations, especially the chronic high blood sugar levels (hyperglycemia), can cause serious complications including heart disease, blindness, kidney failure and amputations due to nerve damage. Currently there is no cure for T1D and no new significant development or permanent therapy for diabetes has emerged in the last 70 years. Islet transplantation while effective is not a scalable therapy and limited to only the most severe T1D patients due to the shortage of cadaveric donor islets. Recent advances in generating insulin producing beta cells from pluripotent stem cells (hPSCs), positions stem cell-based therapy as a promising treatment for a wider population of T1D patients. A stem cell based therapy would replace the damaged beta cells in the patients and allow for a natural production and secretion of insulin to regulate the blood glucose levels. To make stem cell therapy a clinically and commercially viable treatment in diabetes, the following technical hurdles need to be addressed: safety (lack of purity), cost-effective scalability, and lack of immune protection of the implanted cells. Pancryos patented technology, in contrast to other available competing technologies, enables both purification and automation ensuring unparalleled safety and cost-efficient scalability and manufacturability of the final cell product PanINSULA.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PANINSULA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PANINSULA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DNA DS (2019)

DNA Data storage

Read More  

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

LiCrete (2018)

LiCrete - Light transmitting composite material for building purposes

Read More